To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or late recurrence after complete remission (≥
Recurrence after bone marrow transplantation;
Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined
Creatinine ≤1.5×ULN;
1, severe cardiac insufficiency, left ventricular ejection fraction <50%;
Zhu Xiaofan
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Sponsor institution